Prognostic indicators of survival in patients with compensated and decompensated cirrhosis.
about
Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosisNon-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosisCould there be light at the end of the tunnel? Mesocaval shunting for refractory esophageal varices in patients with contraindications to transjugular intrahepatic portosystemic shuntOutcomes of transjugular intrahepatic portosystemic shunts for ascitesPrevention of portal hypertension: from variceal development to clinical decompensationCirrhosis and autoimmune liver disease: Current understandingMagnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease.Sarcopenia as a useful predictor for long-term mortality in cirrhotic patients with ascites.Stage of cirrhosis predicts the risk of liver-related death in patients with low Model for End-Stage Liver Disease scores and cirrhosis awaiting liver transplantationUrinary metabolite profiling offers potential for differentiation of liver-kidney yin deficiency and dampness-heat internal smoldering syndromes in posthepatitis B cirrhosis patients.Reversed portal flow: Clinical influence on the long-term outcomes in cirrhosis.Treatment of Chronic Hepatitis C in the Aged - Does It Impact Life Expectancy? A Decision Analysis.Prevalence of medication discrepancies in patients with cirrhosis: a pilot study.Hepatic Venous Pressure Gradient Predicts Long-Term Mortality in Patients with Decompensated Cirrhosis.Serum Albumin Can Identify Patients With Compensated Cirrhosis With a Good Prognosis.Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint WorkshopHigh Mortality of Cirrhotic Patients With End-Stage Renal Disease.Does adding variceal status to the Child-Turcotte-Pugh score improve its performance in predicting mortality in cirrhosis?Sonoclot signature analysis in patients with liver disease and its correlation with conventional coagulation studies.Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis.Etiology and complications of liver cirrhosis in children:report of a single center from southern iran.Outcome of the Pediatric Patients with Portal Cavernoma: The Retrospective Study for 10 Years Focusing on Recurrent Variceal Bleeding.Cirrhotic Multiorgan Syndrome.Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.The Management of Autoimmune Hepatitis Patients with Decompensated Cirrhosis: Real-World Experience and a Comprehensive Review.Factors affecting mortality and resource use for hospitalized patients with cirrhosis: A population-based studyExploratory study into the unmet supportive needs of people diagnosed with cirrhosis in Queensland, Australia.Relationship and interaction between serum sodium concentration and portal hemodynamics in patients with cirrhosis.Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: A retrospective study.Prognostic Value of Transient Elastography in Human Immunodeficiency Virus-Infected Patients With Chronic Hepatitis C.The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique.Predictors of mortality among patients with compensated and decompensated liver cirrhosis: the role of bacterial infections and infection-related acute-on-chronic liver failure.Compensating effect of minor portal hypertension on the muscle mass loss-related poor prognosis in cirrhosisThe natural history of HCV-related cirrhosis and its temporal progression across the different clinical stages.A low serum Tat-interacting protein 30 level is a diagnostic and prognostic biomarker for hepatocellular carcinoma.Clinical presentation and survival of Asian and non-Asian patients with HCV-related hepatocellular carcinoma.Cell-Based Therapies for Tissue Fibrosis.Vitamin D deficiency is associated with mortality in patients with advanced liver cirrhosis.
P2860
Q24185782-C1469D83-174B-4282-A074-882F2747B1B4Q24185895-26B98F4E-9AD9-4910-AC5F-F065F539A2F0Q26739786-C5E13B96-364C-4423-A6A2-A229A7F72F4CQ26850530-A5883C80-9E42-4D7B-92F8-7FE4A853BA40Q26865665-58799DFD-0238-45BA-A13F-1382AE4CB8BDQ28070154-C7C30EFF-14FD-4258-B672-2D7570E12CE4Q30357059-C4BD3947-552D-4734-A646-E0321BD2EBBEQ34208316-63EC3BDD-5BA7-432A-917F-51F7CB3F4FF1Q34254341-0DA17225-0902-4770-87F1-AA32A7CB2F58Q35034053-2D8F6E51-1990-4FE3-B2C9-258534F27F76Q35925525-215B8ECB-2788-4833-B58F-9F197B126F48Q36076049-73829EFD-4FD6-4ACC-BFAC-1EAF0EC689CDQ36130230-CB792D49-0966-4B7C-82A7-7BDBCEFABEA9Q36418673-AD17A4DA-D6D2-4E22-8169-413F6E5B6C8FQ36853921-6F562401-D11E-4C43-BF95-08C48DD8009EQ36987260-F69F5C3E-8623-4161-83E7-FB85DE7E8BB2Q37207175-0BB79F9A-DF9D-4FA5-BDCB-30C456717620Q37300606-B6C72C8D-3489-42C9-AAE0-2F46FEC4D0A9Q37417325-EDB71A62-4C82-4181-AE63-5870E939B870Q37634003-5F0D62E2-5394-4645-94E0-5ECA89842F9BQ37708319-5F00D95F-5404-4314-BE86-FBB662E019EAQ38469528-ED0A99E5-2469-4BB6-B971-E55B87FE6296Q38538183-23FEE364-75A0-48EC-B475-FFCE8E7E5F89Q38630676-0D0A4740-FF93-411A-BEF8-D3DDBC2BB251Q38925324-D2D663CA-4EDD-4041-B43C-DCB3987BBF89Q38939283-764EE731-C7DA-440A-B34C-6E098E719E55Q38987559-D82F7916-90C9-4039-ACBD-23204E5B0202Q39007521-8452A566-2B6B-4B4E-8FCF-AFF0BBA4FE09Q39459234-F8EF83A3-2CAB-422F-ADD1-B42E77D5CF60Q39818738-72AF4F6E-0A49-4189-89F5-A0AF555C146FQ40053800-B8EF914A-9DF3-4539-865F-F4854C1C6621Q40456677-8CA1D98A-36B4-447F-9608-C0E41B5FDB2CQ40665105-5D5F831A-1A10-4A11-AFCD-0E52B964FEBAQ41387562-A78A4144-8C7D-44EF-B224-1A853298A952Q41455253-194BDB5F-5C69-45BA-ACC0-1EC044BF4243Q41556762-8909D98B-2140-480C-9EA7-CCB11D7E6614Q42232086-EF9E489F-84A3-4F59-B127-DDA01FCF69F9Q42252781-19CA2988-8827-439E-A029-018F06948721Q42369905-F48AA772-AD1E-4CAD-9D96-153C21D4D5C4Q45346508-7AC768F8-C84A-4E71-BCD0-47A5A9E38260
P2860
Prognostic indicators of survival in patients with compensated and decompensated cirrhosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 June 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Prognostic indicators of survi ...... d and decompensated cirrhosis.
@en
Prognostic indicators of survi ...... d and decompensated cirrhosis.
@nl
type
label
Prognostic indicators of survi ...... d and decompensated cirrhosis.
@en
Prognostic indicators of survi ...... d and decompensated cirrhosis.
@nl
prefLabel
Prognostic indicators of survi ...... d and decompensated cirrhosis.
@en
Prognostic indicators of survi ...... d and decompensated cirrhosis.
@nl
P2093
P2860
P1433
P1476
Prognostic indicators of survi ...... d and decompensated cirrhosis.
@en
P2093
Alexander Zipprich
Guadalupe Garcia-Tsao
Matthias M Dollinger
Sebastian Rogowski
Wolfgang E Fleig
P2860
P304
P356
10.1111/J.1478-3231.2012.02830.X
P577
2012-06-11T00:00:00Z